(Q21142734)

English

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

scientific article

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

In more languages

Statements

scholarly article

0 references

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer (English)

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Federica Di Nicolantonio

2

object named as

Federica Di Nicolantonio

author given names

Federica

author last names

Di Nicolantonio

1 reference

PubMed publication ID

17 August 2022

Alberto Bardelli

14

object named as

Alberto Bardelli

author given names

Alberto

author last names

Bardelli

1 reference

PubMed publication ID

17 August 2022

Andrea Sartore-Bianchi

1

object named as

Andrea Sartore-Bianchi

author given names

Andrea

author last names

Sartore-Bianchi

1 reference

PubMed publication ID

17 August 2022

Salvatore Siena

15

object named as

Salvatore Siena

author given names

Salvatore

author last names

Siena

1 reference

PubMed publication ID

17 August 2022

object named as

Miriam Martini

7

author given names

Miriam

author last names

Martini

1 reference

PubMed publication ID

17 August 2022

Silvio Marco Veronese

object named as

Silvio Veronese

12

author given names

Silvio

author last names

Veronese

1 reference

PubMed publication ID

17 August 2022

author name string

Michele Nichelatti

3

author given names

Michele

author last names

Nichelatti

1 reference

PubMed publication ID

17 August 2022

Francesca Molinari

4

author given names

Francesca

author last names

Molinari

1 reference

PubMed publication ID

17 August 2022

Sara De Dosso

5

author given names

Sara

author last names

De Dosso

1 reference

PubMed publication ID

17 August 2022

Piercarlo Saletti

6

author given names

Piercarlo

author last names

Saletti

1 reference

PubMed publication ID

17 August 2022

Tiziana Cipani

8

author given names

Tiziana

author last names

Cipani

1 reference

PubMed publication ID

17 August 2022

Giovanna Marrapese

9

author given names

Giovanna

author last names

Marrapese

1 reference

PubMed publication ID

17 August 2022

Luca Mazzucchelli

10

author given names

Luca

author last names

Mazzucchelli

1 reference

PubMed publication ID

17 August 2022

Simona Lamba

11

author given names

Simona

author last names

Lamba

1 reference

PubMed publication ID

17 August 2022

Milo Frattini

13

author given names

Milo

author last names

Frattini

1 reference

PubMed publication ID

17 August 2022

language of work or name

0 references

publication date

2009

0 references

0 references

4

0 references

10

0 references

e7287

0 references

copyright license

Creative Commons Attribution 4.0 International

2 October 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

19 March 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

7 April 2017

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

7 April 2017

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Mutation of the PIK3CA oncogene in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Systemic therapy for colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

12 September 2017

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

27 September 2017

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2750753

30 May 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

EGFR FISH in colorectal cancer: what is the current reality?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

K-ras mutations and cetuximab in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

21 January 2018

BRAFMutation in Metastatic Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19806185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/19806185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19806185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19806185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line single-agent cetuximab in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19806185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moyamoya disease and moyamoya syndrome

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0007287

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1371/JOURNAL.PONE.0007287

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2009PLoSO...4.7287S

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21142734&oldid=1870910430"